After Reaching Another 52-Week High, Valeant Pharmaceuticals Intl Inc. Should Still Be Avoided at All Costs!

Shares of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) should still be avoided at all costs.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Over the past few days, shares of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) have hit a 52-week high in excess of $28.50, as the company has announced the original offering of US$1 billion in debt, which was then extended to US$1.5 billion. Essentially, debt holders are giving the company a vote of confidence until the maturity of the debt in 2025.

Although this move pushed out the debt maturity schedule for the company, the reality is that the interest rate now being paid to borrow money and maintain operations is an astonishing 9%! The negative aspect of this situation is that the company will be retiring debt with costs between 5% and 7%. Interest costs will continue to increase for two key reasons: the higher-risk profile of the company, and the overall increase in interest rates, which is moving through the general markets. After considering the numbers for the first three quarters of the 2017 fiscal year, I have both good and bad news for the company and investors.

The good news is that the interest expense through the first three quarters of the year has stabilized at US$1.392 billion for 2017 in comparison to US$1.367 billion for the 2016 fiscal year. The bad news is that the interest expense on a year-over-year basis has stabilized just as revenues have declined from US$7.271 billion to US$6.561 billion. The percentage of revenues that are being spent on the servicing of debt has increased from 18.8% to an astonishing 21.2% and is expected to increase even more over the next fiscal year. Over the next year, revenues are expected to decline amid lower revenues.

Although the company has successfully turned a profit in two of the past four quarters, investors need to look behind the curtain and consider what is really happening with the company’s cash flow situation. Over the first three quarters of the year, the company has generated cash from operations (CFO) of US$1.712 billion in comparison to US$1.575 for the same period in fiscal 2016. The interest costs are now taking up more than 80% of CFO — a very dangerous game, indeed.

As is sometimes the case, a highly levered company that has faced the realities of bankruptcy can sometimes provide investors incredible returns, as the leverage employed becomes substantial, and expectations are easily surpassed. In the case of Valeant, many shareholders have come to their senses and sold off at a large loss throughout the year, while those currently holding the security have most probably bought at substantially lower prices, which makes the name one of the least-hated on the street — how times have changed!

With time working against it, investors may be wise to take what they can get, while the house is still standing.

Good luck with this name for 2018!

Should you invest $1,000 in Bausch Health Companies right now?

Before you buy stock in Bausch Health Companies, consider this:

The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and Bausch Health Companies wasn’t one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years.

Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the “eBay of Latin America” at the time of our recommendation, you’d have $20,697.16!*

Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 29 percentage points since 2013*.

See the Top Stocks * Returns as of 3/20/25

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor RyanGoldsman has no position in any of the stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

Confidently Navigate Market Volatility: Claim Your Free Report!

Feeling uneasy about the ups and downs of the stock market lately? You’re not alone. At The Motley Fool Canada, we get it — and we’re here to help. We’ve crafted an essential guide designed to help you through these uncertain times: "5-Step Checklist: How to Prepare Your Portfolio for Volatility."

Don't miss out on this opportunity for peace of mind. Just click below to learn how to receive your complimentary report today!

Get Our Free Report Today

More on Investing

coins jump into piggy bank
Dividend Stocks

The Smartest Canadian Stock to Buy With $2,000 Right Now

The company’s powerful combination of growth, income, and value, positions it well to deliver solid returns, making it a smart…

Read more »

Transparent umbrella under heavy rain against water drops splash background. Rainy weather concept.
Dividend Stocks

This 10.6 Percent Dividend Stock Pays Cash Every Single Month

Are you looking to invest for a rainy day? This 10.6% dividend stock pays cash every month, irrespective of the…

Read more »

money goes up and down in balance
Retirement

Where I’d Invest $10,000 in Canadian Value Stocks for Long-term Growth

Suncor Energy Inc (TSX:SU) is a quality Canadian value stock.

Read more »

A worker gives a business presentation.
Dividend Stocks

Market Dip: Opportunity or Risk This April?

This market dip might have investors worried, but should they be excited instead?

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

Why I’d Add This Top TSX Dividend Stock to My TFSA During the Current Dip

The market is full of volatility right now. Fortunately, this top TSX dividend trades at a discount and pays a…

Read more »

Pile of Canadian dollar bills in various denominations
Dividend Stocks

Invest $20,000 in 2 TSX Stocks for $1,421.09 in Passive Income

Are you looking to bump up your passive income? Then consider these two TSX stocks.

Read more »

Investor wonders if it's safe to buy stocks now
Energy Stocks

Billionaires Might Sell U.S. Stocks and Buy This Canadian Stock to Avoid Tariff Risks

Billionaires might be worried about the future of U.S. stocks with the markets the way they are, and looking for…

Read more »

A plant grows from coins.
Dividend Stocks

Where I’d Invest in Canadian Value Stocks for Long-Term Compounding

When markets plunge, Warren Buffett's wisdom shines: Get greedy when others are fearful. Canadian value stocks like Scotiabank await patient…

Read more »